Roche ties a $387M knot with Warp Dri­ve Bio in col­lab­o­ra­tion spot­light­ing new class­es of an­tibi­otics

Four years af­ter Roche sig­naled its re­turn to the an­tibi­otics field, with mixed re­sults, the phar­ma gi­ant is turn­ing to the ge­nom­ic draw­ing board at Warp Dri­ve Bio to see if it can use the biotech’s tech plat­form to hunt down some com­plete­ly new class­es of an­tibi­otics.

The deal with Roche’s big pRED or­ga­ni­za­tion in Basel — un­der John Reed — comes with an up­front and pre­clin­i­cal mile­stones of $87 mil­lion, with an­oth­er $300 mil­lion on the line for the rest of the de­vel­op­ment and po­ten­tial sales mile­stones un­der the deal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER